First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation
作者:
发布时间
2020-08-12
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文